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Systematic analysis of infectious 
disease outcomes by age shows 
lowest severity in school-age 
children
Judith R. Glynn  1 ✉ & Paul a. H Moss2
The COVID-19 pandemic has ignited interest in age-specific manifestations of infection but surprisingly 
little is known about relative severity of infectious disease between the extremes of age. In a systematic 
analysis we identified 142 datasets with information on severity of disease by age for 32 different 
infectious diseases, 19 viral and 13 bacterial. For almost all infections, school-age children have the 
least severe disease, and severity starts to rise long before old age. Indeed, for many infections even 
young adults have more severe disease than children, and dengue was the only infection that was 
most severe in school-age children. Together with data on vaccine response in children and young 
adults, the findings suggest peak immune function is reached around 5–14 years of age. Relative 
immune senescence may begin much earlier than assumed, before accelerating in older age groups. 
This has major implications for understanding resilience to infection, optimal vaccine scheduling, and 
appropriate health protection policies across the life course.
Introduction
A striking feature of the COVID-19 pandemic is that disease and death are both much less common in children 
than in adults1. This unexplained phenomenon has renewed interest in age patterns of disease. Before COVID-19, 
most contemporary discussion focussed on vulnerabilities at the extremes of age, due to the immature immune 
system in infants, and immune deterioration or ‘immunosenescence’ in the elderly2. There has been little investi-
gation of the comparative response to infection in between theses extremes: indeed, it is generally assumed that 
the response is broadly constant over this period and that immune function remains stable until around 60 years 
of age2.
Infections which have been noted to increase in severity in young adults, such as Spanish influenza and tuber-
culosis, are typically discussed as outliers, and explanations sought. However the medical literature a century ago 
noted that the case fatality rate (deaths/cases) by age is J-shaped for a number of infections, with a ‘honeymoon 
period’ in school-age children and rising fatality throughout adulthood3,4. This pattern, which has never been 
systematically examined, appears to have been largely forgotten, and the explanation for it is unknown.
We present a systematic analysis of severity of infectious disease by age, concentrating on the age at which 
severity starts to rise after childhood. We investigated case fatality rates and other measures of severity for a wide 
range of viral and bacterial infections. We are interested in the effect of age on the outcome of infection, so do not 
include population mortality rates, as they would be influenced by different exposures to infection by age. For 
infections for which there are effective treatments or vaccines, older studies were sought, as the interest is in the 
natural host response. We have included all studies identified by our search that fit our inclusion criteria.
We find that for almost all infections, school-age children have the lowest severity, severity starts to rise well 
before old age, and for many infections, severity is already higher in young adults than in children.
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Results
Information on at least one measure of severity in at least one study was found for 32 infections. Severity is meas-
ured as case fatality rate, or the proportion of cases with severe disease (e.g. the proportion hospitalised), or as the 
proportion with symptomatic disease among those with infection or known exposure. For ease of comparison, a 
figure from the largest dataset for each infection is presented in Figs. 1–4. Details of all identified studies for each 
infection are given in the Supplementary Material1,5–143, together with figures, including the number of cases in 
each age group, where known, and 95% confidence intervals where these could be calculated. Results are shown 
separately by sex when this was available and the sample size was sufficient.
For most infections clinical severity is relatively high in infancy, drops in early childhood and rises in adult-
hood and more steeply into old age. Figures 1–4, Supplementary Figures S1–32 and online-only Table 1 are 





































































































































































































(h) HIV (by age of seroconversion)
Fig. 1 Severity of infectious disease by age for polio, typhoid, tuberculosis, smallpox, chickenpox, measles, 
infectious mononucleosis and HIV. The 95% confidence intervals on the estimates are shown where they  
are known or could be calculated. (a) Polio in England and Wales 1947–50, notified deaths/notified cases 
(23,143 cases)12; (b) Typhoid in small towns in New York State, US, 1915–24, notified deaths/notified cases13; 
(c) Pulmonary TB in Denmark, 1925–34, percent of notified cases dying by 31st December 193421; (d) Measles 
in England and Wales, 1970–88, notified deaths/notified cases29; (e) Smallpox in London Smallpox Hospital, 
UK, 1836–51, case fatality rate among unvaccinated patients35; (f) Chickenpox in France 1997–9, estimated 
hospitalisation rates based on national databases and surveillance40; (g) Infectious mononucleosis in Rochester, 
Minnesota, US, 1950–69, percent hospitalised43; (h) HIV in Europe, North America and Australia, 1983–1996, 
percent dying within 10 years, mother-to-child infections excluded (12,910 cases, survival estimated from 
graph)44.
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For many infections the rise in severity is apparent by age 20 years. For polio, typhoid, tuberculosis and mea-
sles (Fig. 1a–d, Supplementary Figures S1–4) some datasets suggest that the case fatality rate is already higher by 
age 10–14 years than in younger children9,11–13,21,29. A rise in severity by age 15–19 or 15–24 years is seen clearly in 
large datasets for case fatality rates for smallpox35, HIV44, Spanish influenza47,48, pertussis13, and Salmonella55, for 
hospitalisation rates for chickenpox40, and in smaller datasets for hospitalisation for infectious mononucleosis43, 
and case fatality rate for Yellow fever63 (Figs. 1d–h, 2a–d, Supplementary Figures S5–12).
A slightly later rise, from around 20 years, is seen for case fatality rates for typhus15, scarlet fever9, Ebola66, 
meningococcal meningitis70, and Japanese encephalitis73 (Figs. 2e–h, 3a, Supplementary Figures S13–17). For 
cholera, case fatality rates were lowest around 10-24 years in a number of datasets (Supplementary Figure S18)75,76, 
but mortality rates in the large 19th century waterborne outbreaks, in which all age groups would have been 
exposed, were lowest at 5-14 years88,89. For Lassa fever, case fatality rates in Nigeria91,92 increased with age from 
20–30 years but no particular pattern with age was seen in Sierra Leone (Supplementary Figure S19)93,94.
For most of the remaining infections for which information was available, the severity rises with age 
from 30 years (seasonal influenza48, brucellosis96, plague102, probably hepatitis B acute infection99, Fig. 3d–f, 
Supplementary Figures S9c, S20–22), 40 years (Hepatitis A111, SARS114, COVID-19117, MERS-CoV124,125, St Louis 
encephalitis126, Figs. 3g,h 4a–c, Supplementary Figures S23–27) or 50 years (Campylobacter57, Western equine 

















































































































































































Fig. 2 Severity of infectious disease by age for influenza, pertussis, Salmonellosis, yellow fever, typhus, scarlet fever, 
Ebola, and Meningococcal meningitis. The 95% confidence intervals on the estimates are shown where they are 
known or could be calculated. (a) Influenza in Maryland, US, 1918–19, case fatality rate from household surveys47; 
(b) Pertussis in small towns in New York State, US, 1915–24, notified deaths/notified cases13; (c) Salmonellosis in 
Spain 1997–2006, case fatality rate among hospitalised patients (numbers estimated from graph and population 
data)55; (d) Yellow fever in New Orleans, US, 1878, case fatality rate63; (e) Typhus in London Fever Hospital 1848–57, 
case fatality rate15; (f) Scarlet fever in Pennsylvania, US, 1907–12, notified deaths/notified cases9; (g) Ebola in 
Guinea, Liberia and Sierra Leone, 2013–15. case fatality rate66; (h) Meningococcal meningitis in Cyprus, 1908–9, 
case fatality rate70.
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Three infections show different patterns, with greater severity in children than in young adults. The case fatal-
ity rate from diphtheria drops steeply with age in childhood, and continues to fall during adolescence, so the low-
est case fatality rate is in the 20 s and 30 s, before rising from age 40 years (Fig. 4f, Supplementary Figure S30)9,135. 
The proportion of people with Shiga-toxin producing E coli who develop the haemolytic uraemic syndrome 
follows a similar pattern, with a drop during childhood, and the lowest proportion in the 40 s and 50 s before 
rising from age 60 years (Fig. 4g, Supplementary Figure S31)138,139. For Dengue the proportion with more severe 
disease (measured as the proportion with haemorrhagic or any complications or the proportion hospitalised) is 
greatest in school-age children, dropping to a nadir in the 20–30 s before rising again (Fig. 4h, Supplementary 
Figure S32)142.
Discussion
Our findings show that the severity of most infectious diseases is at its lowest in school-age children. Strikingly, 
the severity was higher among young adults than among school-age children for polio12, typhoid13–15, tuber-
culosis21,22, measles29, smallpox34,35, chickenpox40,41, infectious mononucleosis43, HIV44, influenza47,48, pertus-
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Fig. 3 Severity of infectious disease by age for Japanese encephalitis, cholera, Lassa fever, brucellosis, hepatitis 
B, plague, hepatitis A, and SARS The 95% confidence intervals on the estimates are shown where they are 
known or could be calculated. (a) Japanese encephalitis in Korea, 1955–66, notified deaths/notified cases73;  
(b) Cholera in Munich, Germany, 1873–4, notified deaths/notified cases76; (c) Lassa fever in Nigeria, 2018, case 
fatality rate in laboratory confirmed cases91; (d) Brucellosis in Malta, 1936, case fatality rate96; (e) Hepatitis B in 
Alaska, 1971–6, proportion of new infections with symptomatic hepatitis99; (f) Plague in 75 villages in Jalandhar 
District, India, 1897–8, notified deaths/notified cases102; (g) Hepatitis A in England and Wales, 1979–85, 
notified deaths/notified cases111; (h) SARS in Hong Kong, 2003, case fatality rate (numbers estimated from 
incidence and population data)114.
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encephalitis73 cholera76, and perhaps Lassa fever91. Some infections show a slower rise of severity with age after 
childhood (brucellosis96, plague102, coronavirus infections113,115,117,124,125, acute hepatitis B99 and hepatitis A111, St 
Louis encephalitis126, Campylobacter57, and Western equine encephalitis134,) but for most this rise begins well 
before old age. For Diphtheria9,135 and Shiga toxin-producing E coli138,139 severity remains raised in childhood 
and adolescents compared to young or middle-age adults, and for Dengue142 the greatest severity is in school-age 
children.
Since exposure may vary for children and adults we examined case fatality rates and other measures of sever-
ity, not mortality rates. Many reports relied on clinical diagnoses or were based on surveillance data or were 
limited to hospitalised patients, and it is possible that diagnoses, notifications and hospitalisations differ for 
children and adults. In order to measure outcomes that are unaffected by vaccination or effective treatments, 
some of the included studies are old. But even some older studies were carefully conducted. House-to-house 
surveys of smallpox34 and influenza47,48 ensured mild cases and all ages are included. Direct estimates of fatalities 
in well-characterized outbreaks of Yellow fever62,63, meningococcal meningitis70, and viral encephalitides73,126 
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Fig. 4 Severity of infectious disease by age for COVID-19, MERS-CoV, St Louis encephalitis, Western equine 
encephalitis, diphtheria, Escherichia coli, and dengue. The 95% confidence intervals on the estimates are shown 
where they are known or could be calculated. (a) COVID-19 in Spain 2020, notified deaths/notified confirmed 
cases, as of 11 May 2020117; (b) MERS-CoV in Saudi Arabia June 2012-July 2014 and 2017–18, case fatality 
rate124,125; (c) S Louis encephalitis in St Louis, US, 1933, case fatality rate126, (d) Campylobacter in Canada, 
2001–4, percent hospitalised57; (e) Western equine encephalitis in Mannitoba, Canada, 1941, case fatality rate134; 
(f) Diphtheria in London, UK, 1894–1903, notified deaths/notified cases135; (g) E coli 0104/H4 Hamburg, 
Germany, 2011, proportion developing haemolytic uraemic syndrome138; (h) Dengue in Brazil 2000–2014, 
proportion haemorrhagic, with any complications, and hospitalised142.
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tuberculosis21,22 ensured all deaths are included. For each infection the different datasets tell a consistent story. 
The general pattern is remarkable, and unlikely to be explained by biases in the data.
A number of factors may explain these observations. The severity of infectious disease depends on the viru-
lence of the infecting organism, the dose or route of infection, and the response of the host. Variation in strain 
virulence by age is unlikely, and many of the studies reported outbreaks of single strains (e.g. Spanish influenza, 
Ebola, smallpox, typhoid, cholera). Most infections have a single route or mode of infection, and for HIV the 
mode of infection does not explain the age pattern44.
Adolescents and adults may be exposed to higher doses of infectious agents than are younger children, 
through caring responsibilities or because they eat more. Greater exposure often increases the risk of acquir-
ing an infection, but the relationship with disease severity is less consistent. An association between infecting 
dose and severity of disease has been suggested for measles145 and perhaps chickenpox146,147, and for Salmonella 
food-poisoning but not typhoid148–150. Fatal cases of SARS and MERS had a slightly shorter incubation period, 
consistent with a higher infectious dose, but this was not found for influenza151–153, and an association between 
severity and incubation period could be explained by host susceptibility. For Ebola, infecting dose (as estimated 
by degree of exposure to people with Ebola virus disease and their bodily fluids) is strongly associated with the 
risk of disease, but did not influence the case fatality rate67,69. Infectious dose cannot explain the continued rise in 
severity throughout adulthood.
The J-shaped pattern of severity, high in infancy, dropping in early childhood to a minimum around age 10 
years, and rising in adolescence and through adulthood, with a steep increment in old age mirrors that seen for 
all-cause mortality across populations154,155. It is also seen for many of the more frequent causes of death including 
respiratory disease, diarrhoeal disease, and tuberculosis154, consistent with a changing age-specific host response.
Co-morbidities tend to increase with age but are generally low in young adults. Interestingly, in a large study 
of trauma in the US, the case fatality rate, adjusted for severity of injury, only rose from age 55 years onwards156, 
suggesting that the change in resilience to infection at younger ages is immunological, not dependent only on 
co-morbidities or physiological changes.
Further support comes from the immunological response to vaccine challenge by age. In clinical trials of 
human papilloma virus vaccine, the antibody levels to 9 different component vaccine sub-types measured 7 
months post-vaccination decreased with each year increase in age from 9–26 years, with the steepest decline 
between ages 10 and 16 years157. A similar profile was seen in responses to Hepatitis B vaccine in China, with anti-
body titres in subjects vaccinated at ages 15–24 years half of those vaccinated at 5–14 years;158 and in bacteriocidal 
antibody responses to Meningococcal group A conjugate vaccine in West Africa, with lower titres in those aged 
18–29 years at vaccination than in those aged 2–10 or 11–17 years159. However this is not universal: responses by 
age to the Meningococcal B vaccine varied by vaccine strain160.
Humoral responses to natural infection also indicate that immune function may be optimised in children 
and adolescents. Antibody titres against persistent herpesviruses such as cytomegalovirus and varicella zoster 
increase in response to recurrent episodes of viral reactivation so higher titres indicate less effective immune 
control, or re-infection. In the Gambia, where most people are infected with cytomegalovirus in infancy, 
cytomegalovirus-specific antibody levels show a ‘J-shaped’ pattern with age, with the lowest levels (suggesting 
optimal control) in adolescents, rising after age 20 years161. Similarly, Varicella zoster is ubiquitous where there is 
no vaccination, and studies in different settings suggest that antibody levels in seropositive individuals are at their 
lowest (suggesting optimal control) at 8–9 or 15–19 years162,163.
The immune system changes in infancy and old age are well described2. After birth the weak innate immune 
system of neonates strengthens rapidly, and the adaptive immune system develops an expanded repertoire of 
memory B and T cells triggered by infections (and vaccinations), the microbiome, and allergens in food and 
the environment2. With ageing, there is a decline in naïve T-cell numbers and T-cell receptor diversity, cytokine 
production by CD4 and CD8 T-cells is impaired, the CD4 to CD8 ratio is inverted, and the cells of the innate 
immune response function less well164. It is likely that the majority of the data presented here reflect the response 
to initial pathogen exposure, as those who are already fully protected by acquired immunity will not be included 
as cases, and those who are partially protected may have mild disease and not be diagnosed. The primary immune 
response may be particularly affected by ageing. The very high case fatality rates in elderly people observed in 
response to novel pathogens such as COVID-19, MERS, SARS, St Louis encephalitis, and Ebola, may result from 
restriction of the naïve T-cell repertoire.
Studies of immune senescence have focussed largely on those over 60 years, but our data indicate that 
important changes in immune function are apparent at a much younger age. This could be explained by relative 
‘senescence’ of the immune system starting in young adulthood or even earlier165,166. Peak immune function in 
childhood and adolescence, at around age 5–14 years, might represent the intersection of improved function due 
to maturity and increasing antigenic exposure, and decreasing function due to early senescence. This is supported 
by assessment of immune parameters, some of which change almost linearly over the lifespan167, and by changes 
in the thymic cortex and medulla which peak in size at age 4–11 years168, or earlier169.
The severity of infectious disease depends not only on the control of the infectious agent but also on patho-
logical damage arising from the immune response. Dengue is an example where strong immune responses in 
childhood are associated with increased clinical complications due to antibody dependent enhancement170. It has 
been suggested that the balance between an insufficient immune response and an over-active immunopatholog-
ical response is generally more favourable in children4. However it seems surprising that a similar balance would 
be required for the wide range of viral and bacterial infections with similar age-severity patterns presented here, 
including infections in which protection is mainly antibody-mediated (e.g. smallpox) and those in which it is 
predominantly cell-mediated (e.g. tuberculosis).
The increase in infectious disease severity during adolescence suggests that puberty could have a role. Sex 
hormones influence immune responses (reviewed in171,172) but in different ways and with inconsistent findings 
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between studies. Overall, testosterone tends to suppress and oestrogens to enhance the immune response172,173. 
These associations may contribute to the generally higher mortality rate from infectious disease in males and 
higher incidence of autoimmune disease in females173,174. Numerous differences in immune marker con-
centrations and response to infection have been described between males and females, and these increase 
after puberty175. However, where data are available, the increase in severity of disease in young adults com-
pared to children and adolescents was seen in both males and females (e.g. Ebola, tuberculosis, Spanish influ-
enza, polio). The decreased immune response to human papilloma virus vaccine with age, and the profile of 
cytomegalovirus-specific immunity with age, are also similar in males and females157,161,176.
Environmental exposures and heterologous infections may modulate the magnitude and quality of 
the immune response at different ages. For tuberculosis it has been argued that not only HIV but some 
(unknown) sexually and parenterally transmitted virus might trigger progression to disease and explain the age 
distribution177.
Persistent infections, such as herpesviruses, may establish early in life, or increase with age, especially with the 
changing social contact patterns of adolescence. Cytomegalovirus seropositivity has been associated with immu-
nosenescent changes, including a reduction in the naïve T-cell pool and commensurate increase in CD8 + mem-
ory T-cells with a reduced CD4:CD8 ratio165,166,178–181, as well as with increased risk of mortality in older age182,183. 
However, the functional consequence of persistent cytomegalovirus infection appears to vary with age and cyto-
megalovirus may enhance responses to heterologous infections in younger people166,184–186. In most countries 
(and probably everywhere at the time when some of the data we present were collected) almost everyone is 
infected with cytomegalovirus in early childhood161,187, and continuing exposure and multiple infections are 
likely. So if cytomegalovirus has a role in explaining the age-pattern of severity, it may reflect immunological attri-
tion due to the burden of persistent infection or reinfection rather than simple presence or absence of infection188.
The age pattern of severity suggests that natural selection has acted to optimise immune function in child-
hood and adolescence with a subsequent decline during adulthood. Peak function before reproduction seems 
counter-intuitive, but according to life history theory there is a trade-off between the energy required for immune 
response and that required for other functions, such as reproduction and growth189,190. Whilst the energy costs of 
innate immunity are spread throughout the lifetime189,190 the adaptive immune system has high upfront but lower 
running energy costs. Thymic involution conserves energy when sufficient naïve T-cells have been generated189, 
facilitating the metabolic demands of the adolescent growth spurt and secondary sexual development191, but 
leaving the elderly more vulnerable.
SARS-CoV and SARS-CoV-2 appear to have more extreme variation in severity by age than other infections, 
with predominantly mild disease in children, and very high case fatality rates in the elderly. Unusually, there is 
no evidence of higher severity in infants. The reasons for this extreme variation are not yet known, but should be 
considered in the context of the findings of this review.
Appreciating how responses to infections vary by age outside the extremes of age can have major implications. 
Understanding the prevalence and transmission of SARS-CoV-2 in children, and how this differs from influenza, 
is crucial in predicting the role of school closures in the response192. Vaccination programmes that increase the 
average age of infection, can paradoxically increase the numbers of people with severe disease193. This has led to 
targeted vaccination of older children for measles and rubella. The higher vaccine response of younger children 
to human papilloma virus vaccine may lead to a shift in target age groups.
The finding that many infectious diseases are least severe in school-age children suggests that relative immune 
ageing starts far earlier than has previously been recognised. Improved understanding of the mechanisms under-
lying this observation may provide novel opportunities for intervention strategies. Children tend to have lower 
mortality than adults from sepsis, and comparison of their responses is being used in drug discovery194; similar 
approaches could be used for other infections. Comparison of immune response to infections which increase in 
severity in young adults and those that only increase later may give clues to drug and vaccine design. In the midst 
of a pandemic and with increasing antimicrobial resistance, new approaches such as these are desperately needed.
Methods
We sought information on severity of infectious disease by age for a wide range of different infections.
Defining outcome measures. The focus of this study is the host response to infection by age. We are inter-
ested in the outcome of infections or exposure. We have therefore used:
•	 Case fatality rates estimated directly from cohorts of individuals
•	 Case fatality rates estimated from surveillance data, comparing numbers of deaths and numbers of cases
•	 Proportion of cases with severe disease (e.g. the proportion hospitalised)
•	 Proportion with symptomatic disease among those with infection or known exposure
Note that mortality rates, though more readily available, would be misleading, as exposure is likely to vary by age.
Sources of data and possible biases. The most accurate data come from situations in which there is 
active case ascertainment to ensure mild cases are not missed, and active follow-up to ensure outcomes are 
recorded, ideally proving infection through serology or microbiology. But such studies are rare, and imposing 
such strict criteria would leave very little data.
Hospital-based data exclude mild cases, and admission criteria may vary with age, but outcomes are likely to 
be accurately recorded.
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Surveillance data provide some of the largest studies but interpreting the age patterns assumes diagnosis and 
notification are not influenced by age group. Case fatality rates measured from surveillance data can also be 
biased because of the lag between incidence and death. This is a particular problem in ongoing epidemics, and for 
diseases with long duration, but will not necessarily bias the age pattern.
Strains of different virulence could affect different sections of the population. Although it is unlikely that 
strains would differ systematically by age group, studies of single outbreaks of disease avoid this theoretical prob-
lem, but are only available for some infections.
For infections for which effective vaccines or treatments are available there may be very few cases or few severe 
cases, and differential access to or efficacy of vaccines and treatment by age could influence the results. For these 
infections estimates from the older (e.g. pre-antibiotic or pre-vaccine) literature can be helpful.
For endemic infections leading to life-long immunity, disease in adults may be rare or atypical, so estimates 
from isolated (e.g. island) populations are most informative. Similarly, newly-emerged infections, or infections in 
areas where they have not been seen before, will not be affected by partial immunity in older individuals.
Search strategy. Finding sufficiently detailed age-specific information for different diseases is not straight-
forward and a conventional systematic review is not possible. Very few studies are done to look at the effect of 
age on disease outcomes. Most outbreak or surveillance reports do not include enough detail, giving age only as 
a median and range, or giving the age breakdown only for deaths or only for cases. Relevant data are occasionally 
included as background information in studies on other topics.
Information on different infections was found in different ways. PubMed was used to find reports on spe-
cific infections, searching with “case fatality” or “severity” or “hospital*”and “age”, or looking at reports of large 
outbreaks. Outbreak reports were also searched through the Morbidity and Mortality Weekly Report (MMWR) 
produced by the US Centers for Disease Control.
To find suitable studies in the older literature, the journal Public Health was hand-searched from volume 1 
(1888) to volume 59 (1946), the Public Health Bulletin from 1904–1949 and the issues of the Journal of Tropical 
Medicine and Hygiene available on-line (1915–19, 1921, 1923). All pamphlets and reports in the London School 
of Hygiene & Tropical Medicine library open shelves and books in the Wellcome collection library open shelves 
relating to infectious diseases were hand-searched. These include reports from the 19th century onwards. We also 
searched books and reports available electronically from the United States Public Health Service, US National 
Library of Medicine Digital Collections, the London School of Hygiene & Tropical Medicine, or Google on 
plague, cholera and yellow fever. The authors’ literature collection was searched, and relevant references followed 
(snowball searching).
All identified studies that gave information on the age-pattern of severity were included if they satisfied the 
following criteria:
•	 Included children and adults
•	 Data stratified in 10-year age groups or less
•	 At least 100 cases included
•	 Source of data given
All eligible studies were included whatever age-severity pattern they showed. Where the number of cases and 
outcomes was presented, or could be derived, by age group, binomial exact 95% confidence intervals were calcu-
lated for the proportions. For each infection, the relative risk of the outcome (death or other measure of severity) 
in adults was compared to that in children using the largest dataset with information on numbers of individuals 
in the relevant age groups.
Data availability
All datasets are available in an Excel file195. This links to the supplementary material, and includes the origin of 
each dataset.
Code availability
There was no custom code for this analysis
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